Fc工程治疗抗体:最近的进展和未来的方向
Dalia T Abdeldaim1,2, Katharina Schindowski1
1Institute of Applied Biotechnology, University of Applied Science Biberach, 88400 Biberach, Germany.
Pharmaceutics
|October 28, 2023
概括
Fc工程通过修改它们的Fc区域来提高疗效和半衰期来增强治疗抗体. 本综述侧重于使用Fc工程优化效应器功能和双特异性抗体稳定性获得批准的抗体疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 单克隆抗体是癌症和其他疾病的关键治疗方法.
- Fc工程修改了抗体的Fc区域,以改善效应器功能或延长半衰期.
- 在Fc工程中的进步代表了下一代基于抗体的疗法.
研究的目的:
- 审查在已批准的治疗抗体中使用的相关Fc工程策略.
- 要突出微调效应器功能和修改抗体半衰期的方法.
- 讨论Fc工程用于稳定非对称双特异性IgG抗体.
主要方法:
- 分析Fc工程技术,包括糖基工程和Fc区域突变.
- 专注于针对目前已批准的治疗抗体的应用策略.
- 审查增强Fc受体和补充相互作用的方法.
主要成果:
- Fc工程策略已经导致批准的抗体疗法.
- 技术可以改善抗体效应器功能,半衰期和双特定格式.
- 一个不断扩大的Fc工程抗体组合正在临床开发中.
结论:
- 抗病毒工程是开发下一代抗体疗法的重要方法.
- 特定的Fc工程策略是优化抗体性能和稳定性的关键.
- 随着Fc工程的不断演变,在抗体治疗方面有进一步的进步.
相关概念视频
01:31Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
01:29Microorganisms in Medicine and Therapeutics
35
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
35